• International
  • Albania
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czech Republic
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Kosovo
  • North Macedonia
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • Slovenia
  • Switzerland (German)
  • Switzerland (French)
  • Media
  • Meet us
  • Careers
  • Contact
ewopharma
  • Business Development
    • Licensing
    • Strategic Therapeutic Areas
    • Territory
  • Partners & Brands
    • Testimonials
  • About Ewopharma
    • Vision/Mission
    • Our Values
    • Our Strategy
    • Leadership
    • Corporate Responsibility
    • Territory
  • Media
  • Meet us
  • Careers
  • Contact
  • International
  • Albania
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czech Republic
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Kosovo
  • North Macedonia
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • Slovenia
  • Switzerland (German)
  • Switzerland (French)
 

Media

Our Logo

Download Logo

CONTACT

Ewopharma AG
Vordergasse 43
8200 Schaffhausen
Switzerland

Tel.: +41 52 633 09 99
E-Mail: pr@remove-this.ewopharma.com

PRESS RELEASES

  • 1
  • 2
  • 3
  • 4
  • Next
15.04.2026

Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage Ⅲ NSCLC

Read more
26.02.2026

BioGaia AB extends long-standing distribution partnership with Ewopharma

Read more
16.12.2025

Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication

Read more
15.04.2025

Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria

Read more
31.07.2024

European Commission Approves Sugemalimab

Read more
  • 1
  • 2
  • 3
  • 4
  • Next

Ewopharma AG
Vordergasse 43
8200 Schaffhausen
Switzerland

CONTACT

Phone: +41 52 633 09 99
E-mail:  info@remove-this.ewopharma.com

Contact for reporting side effects:

pharmacovigilance@remove-this.ewopharma.com

  • Privacy Policy
  • Cookie Policy
  • Imprint
  • VPOIS

© Copyright 2022, Ewopharma AG